Industry interest in rising on whether oral treatments used to treat anemia in dialysis patients will be covered by health insurance in Korea.

The drugs have long been approved in Korea since 2020, but one of the products recently withdrew its license. The other two have yet to be reviewed for reimbursement, raising interest.

According to industry sources on the 3rd, AstraZeneca dropped the license for its Evrenzo Tab (Roxadustat, AstraZeneca), which is used to treat symptomatic anemia in patients with chronic kidney disease, on April 30. The market withdrawal comes more than 3 years after its approval in July 2021.

The drug was praised for improving the convenience of ane